Skip to main content

READY WHEN THEY ARE

READY WHEN THEY ARE

Esperoct® provides storage temperatures up to 104°F for up to 3 months or 86˚F for up to 12 months and can be reconstituted in just 3 steps with MixPro®.1

Esperoct® storage temperature
Esperoct® storage temperature

WHAT’S INCLUDED IN THE ESPEROCT® PACKAGE:

Single-dose vial with color-coded cap

Differentiate dose strengths through color-coded vial caps.1

Esperoct® multiple vial sizes

Vial adapter

Connects the syringe and vial, with a 25-μm inline particle filter.1

Esperoct®  vial adapter

MixPro® prefilled diluent syringe

Latex-free syringe contains 4 mL of 0.9% saline solution—works with all dose strengths.1

MixPro® device

BASIC RECONSTITUTION IN 3 STEPS

1. Attach

Esperoct® reconstitute in 3 steps

2. Twist

Esperoct® reconstitute in 3 steps

3. Mix

Esperoct® reconstitute in 3 steps

After mixing, the reconstituted solution can be stored for use within 4 hours at up to 86˚F.1

This is not the complete Esperoct® Instructions for Use. Please refer to the Instructions for Use provided with the Prescribing Information.

For your patients: Starting Esperoct®.

Novo Nordisk is here to help your hemophilia A patients who want to make the switch to Esperoct®. Learn about our trial prescriptiona and product support programs.

Esperoct® adult walking outside
Esperoct® adult walking outside

aPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance or who are uninsured, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.

Count on the proven safety profile of Esperoct®.

~2-minute infusion for your patients.

Esperoct® infusion

Fast infusions to fit in your patients’ lives.1

Register to get the latest updates about Esperoct®

Register to get the latest updates about Esperoct®

Selected Important Safety Information

Contraindications
  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications
  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
Adverse Reactions
  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions

Please click here for Prescribing Information

Reference:

  1. Esperoct [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2019.